MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN
DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.
* Boehringer Ingelheim will be commencing a new collaboration with Thoeris
GmbH with the goal of advancing a first-in-class approach for the treatment
of urea cycle disorders (UCDs) independent of the underlying monogenetic
* UCDs are genetic disorders with highly variable onset and severity, causing
excess ammonia levels in the blood, which can lead to irreversible brain
damage, coma and death
* This collaboration is part of Boehringer Ingelheim's commitment to
leveraging emerging science to deliver transformative treatment options for
patients with high medical need.
INGELHEIM, Germany & VIENNA --(BUSINESS WIRE)--26.10.2021--
Boehringer Ingelheim and Thoeris GmbH announce a collaboration and license
agreement with the aim to investigate novel first-in-class therapies for
patients with urea cycle disorders (UCDs). UCDs are rare diseases caused by
genetic liver dysfunctions leading to excess ammonia levels in the blood for
which only insufficient treatments exist to date. Thoeris has developed a novel
approach that could transform the treatment of patients with these conditions.
Boehringer Ingelheim will contribute its expertise in drug discovery and
development to advance potential medications into the clinic.
'The new UCD therapy approach developed by Thoeris could enable disease symptom
control by boosting a pathway to detoxify the excess ammonia levels in the
body. We are very excited to team up with the scientists at Boehringer
Ingelheim to develop our approach into a practical treatment for acute
intervention and chronic therapy,' stated Tamara Nicolson, Ph.D., CEO of
'Strengthening emerging medical science to offer new therapies that change
medical practice and improve quality of life of patients is a key element of
Boehringer Ingelheim's strategy,' said Detlev Mennerich, Ph.D., Global Head of
Research Beyond Borders at Boehringer Ingelheim. 'We very much look forward to
working with Thoeris, aiming to deliver a novel therapeutic option to patients
suffering from UCDs, independent of the underlying inherited mutation.'
This collaboration stems from the therapeutic commitment of Boehringer
Ingelheim's Research Beyond Borders (RBB) group, which acts as an 'innovation
radar' for Boehringer Ingelheim's R&D to explore unchartered scientific
territories. RBB collaborates with leading academic and biotech partners to
unleash newly-discovered disease biology, bringing Boehringer Ingelheim's
excellence in drug discovery, drug development and manufacturing on board in
order to translate these pioneering discoveries into innovative therapies with
breakthrough potential that could change medical practice.
In people with UCDs, one of several proteins involved in the degradation of
ammonia is missing or defective. This leads to hyperammonemia, a build-up of
toxic concentrations of ammonia in the body, which is associated with acute
pathological effects such as cerebral edema, lethargy, neurologic dysfunction
and potentially death. In the long term, patients suffering from UCDs face
developmental delay, cognitive disabilities, and seizures. Due to insufficient
treatment options, chronic UCDs are associated with recurrent crises in which
ammonia levels escalate out of control, worsening the condition. The only
available curative option to date is liver transplantation.
Please click on the following link for 'Notes to Editors':
View source version on businesswire.com: https://www.businesswire.com/news/home
Dr. Reinhard Malin
Head of Communications Innovation Unit
Boehringer Ingelheim Corporate Center GmbH
Media + PR
P: +49 6132 77-90815
Senior Associate Director, Media and Corporate Reputation
Boehringer Ingelheim U.S.
Media + PR
P: +1 203-791-6672
26.10.2021 Veröffentlichung einer Pressemitteilung, übermittelt durch DGAP - ein Service der EQS Group AG.
Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich.
Die DGAP Distributionsservices umfassen gesetzliche Meldepflichten, Corporate News/Finanznachrichten und Pressemitteilungen.
Medienarchiv unter http://www.dgap.de